Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review.

Autor:	Ahmad K; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Manongi NJ; Family Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Rajapandian R; Trauma and Orthopedics, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Moti Wala S; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Al Edani EM; Dermatology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Samuel EA; Physical Medicine and Rehabilitation, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Arcia Franchini AP; Research, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 31; Vol. 16 (8), pp. e68316. Date of Electronic Publication: 2024 Aug 31 (Print Publication: 2024).
DOI:	10.7759/cureus.68316
Abstrakt:	Statins are among the most widely prescribed drugs for treating dyslipidemia and reducing the incidence of heart disease and stroke. However, they come with a wide range of side effects, from myopathy to necrotizing rhabdomyolysis, as well as diabetes, hepatotoxicity, and sleep problems. The most common side effect of statins is statin-induced myopathy, often leading to discontinuation of statin therapy and noncompliance in many patients. This study aims to assess the effectiveness of coenzyme Q10 (CoQ10) supplementation as a treatment for patients with statin-induced myopathy. This systematic review was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Relevant studies were identified through searches of Medline, PMC, PubMed, Science Direct, and Google Scholar. Only randomized control trials and meta-analyses of oral CoQ10 supplementation versus placebo in adults with statin-associated myalgia were included. The risk of bias was assessed using the Cochrane Risk of Bias tool (The Cochrane Collaboration, London, England, UK) and the measurement tool for the "assessment of multiple systematic reviews" (AMSTAR tool). Out of 5,000 records identified, only five were selected for this review: one meta-analysis and four randomized controlled trials. All of these studies were conducted between 2010 and 2023, involving a total of 800 patients. All randomized controlled trials showed improvement in statin-associated myopathy with CoQ10 supplementation, along with or without a reduced dosage of statins, without any notable side effects of CoQ10. Therefore, it can be deduced that CoQ10 supplementation significantly ameliorates statin-induced musculoskeletal symptoms. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Ahmad et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu